Italia markets closed

SWTX Jan 2025 70.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,7000-0,1000 (-12,50%)
Alla chiusura: 09:30AM EDT
Schermo intero
Chiusura precedente0,8000
Aperto0,6500
Denaro0,0000
Domanda2,6000
Prezzo d'esercizio70,00
Scadenza2025-01-17
Min-Max giorno0,6500 - 0,7000
Contratto - Min-MaxN/D
Volume2
Open Interest16
  • GlobeNewswire

    SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

    – Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (